Journal of Molecular and Cellular Cardiology
Volume 44, Issue 3 , Pages 477-485 , March 2008

Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway

Received 16 August 2007 ,Revised 30 September 2007 ,Accepted 1 October 2007.

References 

  1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823
  2. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987;59:256–262
  3. La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet. 1998;351:478–484
  4. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation. 1998;98:1510–1516
  5. Potter EK. Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y?. Neurosci Lett. 1985;54(2–3):117–121
  6. Smith-White MA, Iismaa TP, Potter EK. Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse. Br J Pharmacol. 2003;140(1):170–178
  7. Ilebekk A, Bjorkman JA, Nordlander M. Influence of endogenous neuropeptide Y (NPY) on the sympathetic–parasympathetic interaction in the canine heart. J Cardiovasc Pharmacol. 2005;46(4):474–480
  8. Ullman B, Franco-Cereceda A, Hulting J, Lundberg JM, Sollevi A. Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J Intern Med. 1990;228(6):583–589
  9. Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JE, et al. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med. 1989;86(1):43–48
  10. Hulting J, Sollevi A, Ullman B, Franco-Cereceda A, Lundberg JM. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res. 1990;24(2):102–108
  11. Lundberg JM, Hua XY, Franco-Cereceda A. Effects of neuropeptide Y (NPY) on mechanical activity and neurotransmission in the heart, vas deferens and urinary bladder of the guinea-pig. Acta Physiol Scand. 1984;121(4):325–332
  12. Potter E. Presynaptic inhibition of cardiac vagal postganglionic nerves by neuropeptide Y. Neurosci Lett. 1987;83(1–2):101–106
  13. Pardini BJ, Lund DD, Puk DE. Sites at which neuropeptide Y modulates parasympathetic control of heart rate in guinea pigs and rats. J Auton Nerv Syst. 1992;38(2):139–145
  14. Potter EK. Cardiac vagal action and plasma levels of neuropeptide Y following intravenous injection in the dog. Neurosci Lett. 1987;77(2):243–247
  15. Smith-White MA, Wallace D, Potter EK. Sympathetic–parasympathetic interactions at the heart in the anaesthetised rat. J Auton Nerv Syst. 1999;75(2–3):171–175
  16. Smith-White MA, Hardy TA, Brock JA, Potter EK. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br J Pharmacol. 2001;132(4):861–868
  17. Smith-White MA, Herzog H, Potter EK. Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept. 2002;103(2–3):105–111
  18. Sosunov EA, Anyukhovsky EP, Rosen MR. Effects of exogenous neuropeptide Y on automaticity of isolated Purkinje fibers and atrium. J Mol Cell Cardiol. 1996;28(5):967–975
  19. Michel MC. Receptors for neuropeptide Y: multiple subtypes and multiple second messengers. Trends Pharmacol Sci. 1991;12(10):389–394
  20. Balasubramaniam AA. Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides. 1997;18(3):445–457
  21. Herring N, Golding S, Paterson DJ. Pre-synaptic NO-cGMP pathway modulates vagal control of heart rate in isolated adult guinea pig atria. J Mol Cell Cardiol. 2000;32:1795–1804
  22. Herring N, Paterson DJ. Nitric oxide-cGMP pathway facilitates acetylcholine release and bradycardia during vagal nerve stimulation in the guinea-pig in vitro. J Physiol. 2001;535(2):507–518
  23. Herring N, Zaman JA, Paterson DJ. Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway. Am J Physiol Heart Circ Physiol. 2001;281(6):H2318–H2327
  24. McCullough LA, Egan TM, Westfall TC. Neuropeptide Y inhibition of calcium channels in PC-12 pheochromocytoma cells. Am J Physiol. 1998;274(5 Pt 1):C1290–C1297
  25. Heredia MP, Fernandez-Velasco M, Benito G, Delgado C. Neuropeptide Y increases 4-aminopyridine-sensitive transient outward potassium current in rat ventricular myocytes. Br J Pharmacol. 2002;135(7):1701–1706
  26. Wang H, Morris JF. Presence of neuronal nitric oxide synthase in the suprachiasmatic nuclei of mouse and rat. Neuroscience. 1996;74:1059–1068
  27. Sears CE, Choate JK, Paterson DJ. Inhibition of nitric oxide synthase slows heart rate recovery from cholinergic activation. J Appl Physiol. 1998;84:1596–1603
  28. Wetzel GT, Brown JH. Relationships between choline uptake, acetylcholine synthesis and acetylcholine release in isolated rat atria. J Pharmacol Exp Ther. 1983;226(2):343–348
  29. Dumont Y, Cadieux A, Doods H, Pheng LH, Abounader R, Hamel E, et al. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol. 2000;129(6):1075–1088
  30. Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1989;159(2):548–553
  31. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1990;172(3):993–999
  32. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990;265(9):5267–5272
  33. Schwertfeger E, Klein T, Vonend O, Oberhauser V, Stegbauer J, Rump LC. Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(5):455–461
  34. Yu XC, Wang HX, Pei JM, Wong TM. Anti-arrhythmic effect of kappa-opioid receptor stimulation in the perfused rat heart: involvement of a cAMP-dependent pathway. J Mol Cell Cardiol. 1999;31(10):1809–1819
  35. Mielke M, Paterson DJ, Sang AE, Radda GK, Clarke K. The mechanism underlying the positive inotropic effect of angiotensin II in the isolated perfused rabbit heart: a 31P NMR study. Int J Biochem Cell Biol. 2003;35(6):984–991
  36. Ishac EJ, De Luca A. The influence of activation or inhibition of protein kinase C on the release of radioactivity from rat isolated atria labelled with [3H]-noradrenaline. Br J Pharmacol. 1988;94(3):713–720
  37. Cho H, Youm JB, Earm YE, Ho WK. Inhibition of acetylcholine-activated K(+) current by chelerythrine and bisindolylmaleimide I in atrial myocytes from mice. Eur J Pharmacol. 2001;424(3):173–178
  38. Seebeck J, Schmidt WE, Kilbinger H, Neumann J, Zimmermann N, Herzig S. PACAP induces bradycardia in guinea-pig heart by stimulation of atrial cholinergic neurones. Naunyn Schmiedebergs Arch Pharmacol. 1996;354(4):424–430
  39. Toth PT, Bindokas VP, Bleakman D, Colmers WF, Miller RJ. Mechanism of presynaptic inhibition by neuropeptide Y at sympathetic nerve terminals. Nature. 1993;364(6438):635–639
  40. Hirning LD, Fox AP, Miller RJ. Inhibition of calcium currents in cultured myenteric neurons by neuropeptide Y: evidence for direct receptor/channel coupling. Brain Res. 1990;5:532(1–2):120–130
  41. Wiley JW, Gross RA, Lu YX, Macdonald RL. Neuropeptide Y reduces calcium current and inhibits acetylcholine release in nodose neurons via a pertussis toxin-sensitive mechanism. J Neurophysiol. 1990;63(6):1499–1507
  42. McDonald RL, Vaughan PF, Beck-Sickinger AG, Peers C. Inhibition of Ca2+ channel currents in human neuroblastoma (SH-SY5Y) cells by neuropeptide Y and a novel cyclic neuropeptide Y analogue. Neuropharmacology. 1995;34(11):1507–1514
  43. Danson EJ, Zhang YH, Sears CE, Edwards AR, Casadei B, Paterson DJ. Disruption of inhibitory G-proteins mediates a reduction in atrial beta-adrenergic signaling by enhancing eNOS expression. Cardiovasc Res. 2005;67(4):613–623

PII: S0022-2828(07)01266-7

doi: 10.1016/j.yjmcc.2007.10.001

Journal of Molecular and Cellular Cardiology
Volume 44, Issue 3 , Pages 477-485 , March 2008

Article Tools

* Image Usage & Resolution